Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

317

HTML

2370

Tables (1-3)

220

Sum=2907

Mar 15, 2004 (publication date) through Feb 8, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Mar 15, 2004; 10(6): 910-912
Published online Mar 15, 2004. doi: 10.3748/wjg.v10.i6.910

Table 3 Control of hepatitis activity[22]

	n	Activehepatitis (%)
Lamivudine treatment during pregnancy	38	0 (0.00)
Stop lamivudine while pregnant	2	2 (100.00)
Stop lamivudine	41	7 (17.07)

Citation: Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004; 10(6): 910-912
URL: https://www.wjgnet.com/1007-9327/full/v10/i6/910.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i6.910